NYLIM
BVS icon

New York Life Investment Management’s Bioventus BVS Stock Holding History

New York Life Investment Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-39,957
Closed -$104K – 1227
2022
Q4 		$104K Buy
39,957
+4,261
+12% +$18.6K ﹤0.01% 1193
2022
Q3 		$250K Buy
35,696
+2,622
+8% +$20.5K ﹤0.01% 1150
2022
Q2 		$226K Buy
+33,074
New +$337K ﹤0.01% 1214

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

New York Life Investment Management's BVS Position: Q1 2023 in Review

New York Life Investment Management sold out of Bioventus (BVS) in Q1 2023, closing a stake of 39,957 shares — an estimated $104K sold.

New York Life Investment Management first reported a position in BVS in Q2 2022 and held it in 3 quarters. The position peaked at $250K in Q3 2022. 71 funds tracked by Wall St. Rank hold BVS as of Q1 2023.

  • New York Life Investment Management reported no remaining Bioventus position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 39,957 Bioventus shares in Q1 2023, an estimated $104K.
  • New York Life Investment Management first reported a position in Bioventus in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Bioventus position peaked at $250K in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Bioventus as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.